Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10063346 | 0.81 | NEK2 (0.40) | LRRK2 | |
| SCHEMBL21739433 | 0.80 | TOP2A (0.33) | SMN1; SMN2 | |
| SCHEMBL24246661 | 0.77 | — | — | |
| SCHEMBL3422752 | 0.76 | PIK3CD (0.35) | — | |
| SCHEMBL3535456 | 0.75 | GAA (0.32) | SMN1; SMN2 | |
| SCHEMBL22259418 | 0.74 | SLC6A2 (0.33) | LRRK2SMN1; SMN2 | |
| SCHEMBL22449836 | 0.74 | SLC6A2 (0.33) | LRRK2SMN1; SMN2 | |
| SCHEMBL22449831 | 0.73 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL31616293 | 0.72 | SLC6A2 (0.32) | LRRK2 | |
| SCHEMBL21886745 | 0.72 | NR1H2 (0.39) | SMN1; SMN2CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-20130018037-A1 | Compounds - 801 | ASTRAZENECA UK LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018037-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | LRRK2 625/4885SMN1; SMN2 2163/4885CRBN 1746/4885 |
| US-20120322788-A1 | Compouds | PKD1, SBDS, ABCB11 | LRRK2 3867/4885SMN1; SMN2 3300/4885CRBN 2036/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | LRRK2 2366/4885SMN1; SMN2 2946/4885CRBN 4359/4885 |
| US-20110053909-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | LRRK2 625/4885SMN1; SMN2 2163/4885CRBN 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.